Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma
Kairos Pharma (NYSE American: KAPA) presented preclinical data on its GITR agonist, KROS101, at the AACR-JCA Joint Conference. The research demonstrated KROS101's effectiveness in enhancing T cell infiltration, proliferation, and cancer cell-killing abilities in melanoma mouse models and human glioblastoma in vitro.
The compound showed significant results in reducing melanoma tumors in human GITR knock-in mouse models, outperforming the GITR antibody TRX518. KROS101 works by stabilizing the active form of GITRL, reducing suppressive T-cells while enhancing cytotoxic T cells. The presentation highlighted the compound's potential as a novel cancer therapy, particularly for melanoma and glioblastoma treatment.
Kairos Pharma (NYSE American: KAPA) ha presentato dati preclinici sul suo agonista GITR, KROS101, alla Conferenza congiunta AACR-JCA. La ricerca ha dimostrato l'efficacia di KROS101 nell'aumentare l'infiltrazione delle cellule T, la proliferazione e le capacità di uccisione delle cellule tumorali nei modelli murini di melanoma e nel glioblastoma umano in vitro.
Il composto ha mostrato risultati significativi nella riduzione dei tumori di melanoma nei modelli murini GITR knock-in umani, superando l'anticorpo GITR TRX518. KROS101 agisce stabilizzando la forma attiva di GITRL, riducendo le cellule T soppressive mentre potenzia le cellule T citotossiche. La presentazione ha evidenziato il potenziale del composto come una nuova terapia contro il cancro, in particolare per il trattamento del melanoma e del glioblastoma.
Kairos Pharma (NYSE American: KAPA) presentó datos preclínicos sobre su agonista GITR, KROS101, en la Conferencia Conjunta AACR-JCA. La investigación demostró la efectividad de KROS101 en el aumento de la infiltración de células T, la proliferación y las habilidades para matar células cancerosas en modelos murinos de melanoma y glioblastoma humano in vitro.
El compuesto mostró resultados significativos en la reducción de tumores de melanoma en modelos murinos GITR knock-in humanos, superando al anticuerpo GITR TRX518. KROS101 actúa estabilizando la forma activa de GITRL, reduciendo las células T supresoras mientras potencia las células T citotóxicas. La presentación destacó el potencial del compuesto como una nueva terapia contra el cáncer, particularmente para el tratamiento del melanoma y del glioblastoma.
카이로스 제약 (NYSE American: KAPA)는 AACR-JCA 공동 회의에서 GITR 작용제인 KROS101에 대한 전임상 데이터를 발표했습니다. 연구 결과, KROS101은 멜라노마 쥐 모델과 인간 신경교종의 세포 배양에서 T 세포 침투, 증식 및 암세포 제거 능력을 향상시키는 데 효과적임을 보여주었습니다.
이 화합물은 인간 GITR knock-in 쥐 모델에서 멜라노마 종양을 줄이는 데 상당한 결과를 나타내었으며, GITR 항체인 TRX518보다 더 우수한 성과를 보였습니다. KROS101은 GITRL의 활성 형태를 안정화하여 억제성 T 세포를 줄이고 세포독성 T 세포를 증가시켜 작용합니다. 발표에서는 이 화합물이 멜라노마와 신경교종 치료를 위한 새로운 암 치료제로서의 잠재력을 강조했습니다.
Kairos Pharma (NYSE American: KAPA) a présenté des données précliniques sur son agoniste GITR, KROS101, lors de la Conférence conjointe AACR-JCA. La recherche a démontré l'efficacité de KROS101 à améliorer l'infiltration des cellules T, leur prolifération et leurs capacités d'élimination des cellules cancéreuses dans des modèles murins de mélanome et in vitro dans le glioblastome humain.
Le composé a montré des résultats significatifs dans la réduction des tumeurs de mélanome dans des modèles murins humains GITR knock-in, surpassant l'anticorps GITR TRX518. KROS101 agit en stabilisant la forme active de GITRL, réduisant les cellules T suppressives tout en augmentant le nombre de cellules T cytotoxiques. La présentation a mis en avant le potentiel de ce composé en tant que nouvelle thérapie contre le cancer, en particulier pour le traitement du mélanome et du glioblastome.
Kairos Pharma (NYSE American: KAPA) präsentierte auf der AACR-JCA Joint Conference präklinische Daten zu ihrem GITR-Agonisten KROS101. Die Forschung zeigte die Wirksamkeit von KROS101 in der Verbesserung der T-Zell-Infiltration, -proliferation und -tötungsfähigkeiten von Krebszellen in Melanom-Mausmodellen und humanem Glioblastom in vitro.
Die Verbindung zeigte signifikante Ergebnisse bei der Reduzierung von Melanomtumoren in menschlichen GITR knock-in Mausmodellen und übertraf den GITR-Antikörper TRX518. KROS101 wirkt, indem es die aktive Form von GITRL stabilisiert, unterdrückende T-Zellen reduziert und zytotoxische T-Zellen steigert. Die Präsentation hob das Potenzial des Wirkstoffs als neuartige Krebstherapie hervor, insbesondere für die Behandlung von Melanom und Glioblastom.
- Preclinical data showed KROS101's superior performance compared to existing GITR antibody TRX518
- Demonstrated effectiveness in both melanoma and glioblastoma models
- Successfully reduced melanoma tumors in human GITR knock-in mouse model
- Still in early preclinical stage, far from market approval
- Results to laboratory and animal studies, no human trial data yet
Insights
The preclinical data presentation for KROS 101 represents a significant scientific advancement in cancer immunotherapy, particularly for treating aggressive cancers like melanoma and glioblastoma. The compound's novel mechanism of action as a GITR agonist addresses a critical area in cancer treatment by enhancing the body's immune response against tumors.
The data is particularly compelling for three reasons:
- Superior efficacy compared to TRX518, a previously clinically-tested GITR antibody, suggesting potential advantages over existing approaches
- Dual activity in both melanoma and glioblastoma models, indicating broad therapeutic potential across different cancer types
- Novel mechanism of stabilizing GITRL's active form, which could potentially result in better clinical outcomes than current immunotherapy approaches
From a development perspective, the strong preclinical data suggests a higher probability of success in future clinical trials. However, investors should note that the path from preclinical to approved therapy is long and complex, typically requiring 5-7 years and multiple clinical trial phases. The positive results in both melanoma and glioblastoma models could potentially support parallel development programs, maximizing the commercial opportunity while diversifying risk.
The immunotherapy market for melanoma and glioblastoma represents a significant commercial opportunity. Current treatments for these cancers often have efficacy, particularly for glioblastoma, which has a poor prognosis and treatment options. A successful GITR-targeting therapy could potentially capture substantial market share in these indications.
While these results are promising, it's important to note that this is still early-stage data and successful preclinical results don't guarantee clinical success. The company will need to demonstrate safety and efficacy in human trials, secure substantial funding for clinical development and navigate regulatory requirements before commercialization becomes possible.
In the talk, titled, “KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor T Cell Responses and Reprogramming the Tumor Microenvironment,” recent findings from the Company’s in vivo work on the compound was presented. The results, which can be found here, demonstrated that KROS 101 is a potent GITR ligand agonist that enhances T cell infiltration, proliferation, and ability to kill cancer cells in mouse models of melanoma and in human glioblastoma in vitro, while effectively reducing T reg-mediated suppression. KROS 101 showed significant activity in enabling T cell proliferation and killing of melanoma tumors in vivo as well as glioblastoma tumor in vitro.
GITRL, one of the checkpoint cytokines in the family of tumor necrosis factor ligand family, regulates T cell function in autoimmunity and cancer. KROS 101 stabilizes the active form of GITRL and thereby reduces suppressive T-cells and enhances cytotoxic T cells. In a preclinical study, KROS 101 reduced melanoma tumor in a human GITR knock-in mouse model compared to those in mice treated with the GITR antibody TRX518, which was recently in clinical trials for solid cancers.
Dr. Ramachandran Murali, VP of Research and Development at Kairos Pharma and co-inventor of KROS 101, stated, “The performance of KROS 101 as a central mediator of T cell expansion in cancer has been supported by these studies.”
Dr. John Yu, CEO of Kairos Pharma and co-inventor, added that “the preclinical data support the potential to exploit GITR as a lever for T cell expansion and novel therapy for cancer.”
The American Association for Cancer Research (AACR) and Japanese Cancer Association (JCA) hosted the 13th AACR-JCA Joint Conference from February 1-5, 2025 at the Hyatt Regency Maui, in
About Kairos Pharma Ltd.
Based in
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus filed with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by
View source version on businesswire.com: https://www.businesswire.com/news/home/20250206902972/en/
CORE IR
Louie Toma
investors@kairospharma.com
Source: Kairos Pharma, Ltd.
FAQ
What are the key findings of KAPA's KROS101 preclinical trials in 2025?
How does Kairos Pharma's KROS101 work against cancer cells?
What types of cancer is KAPA's KROS101 being developed to treat?
What advantages does KROS101 show over TRX518 in melanoma treatment?
